Navigation Links
Pharmacyclics Reports Third Quarter 2013 Results
Date:11/7/2013

ults, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our transition report on Form 10-K for the six month period ended December 31, 2012 and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

 Pharmacyclics, Inc.Condensed Consolidated Balance Sheets(unaudited; in thousands)

 Sep. 30,Dec. 31,20132012AssetsCash, cash equivalents and marketable securities 1$ 560,100$ 317,114Other current assets 264,31029,378Total current assets624,410346,492Property and equipment, net20,8566,403Other assets3,0332,234Total assets$ 648,299$ 355,129Liabilities and Stockholders' EquityDeferred revenue - current portion$
7,411$
8,139Other current liabilities59,77521,118Total current liabilities67,18629,257Deferred revenue - non-current portion52,05462,562Deferred rent707784Total liabilities119,94792,603Stockholders' equity528,352262,526Total liabilities and stockholders' equity$ 648,299$ 355,1291Marketable securities$   11,667$
9,6812As of September 30, 2013 and December 31, 2012, Other current assets includes $52.2 million and $26.6 million, respectively, due to the Company from Janssen under the collaboration and license agreement related to cost sharing and Excess Amounts. Pharmacyclics, Inc.Condensed Consolidated Statements of Operations (unaudited; in thousands, except per share data) Three Months EndedNine Months EndedSep. 30, Sep. 30, Sep. 30, Sep. 30, 2013201220132012Revenue:  Licen
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
2. Pharmacyclics Reports Second Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
4. Pharmacyclics Reports First Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
6. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Pharmacyclics, Inc. Prices Public Offering of Common Stock
9. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
10. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
11. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative biopharmaceutical ... present at the Barclays Global Healthcare Conference ... Miami Beach Hotel in Miami , ... M.D., President and Chief Executive Officer of Aratana Therapeutics, ...
(Date:3/4/2015)... 4, 2015  Bayer HealthCare today announced that ... accepted the company,s Biologics License Application (BLA) for ... is seeking FDA approval of the investigational compound, ... hemophilia A in children and adults. ... therapies to hemophilia A patients who need them," ...
(Date:3/4/2015)... -- Halyard Health, Inc. (NYSE: HYH ) today ... and related key planning assumptions. "This is ... our fourth quarter results, our first as an independent ... a smooth separation from Kimberly-Clark and I,m pleased with ... growth and margin improvement in the fourth quarter while ...
Breaking Medicine Technology:Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 2Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 4Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 5Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 6Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 7Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 8Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 9Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 10Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 11Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 12Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 13Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 14Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 15Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 16Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 17Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 18Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 19Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 20Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 21Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 22Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 23Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 24Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 25Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 26Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 27Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 28Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 29Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 30Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 31
... LAKE FOREST, Ill., March 5, 2012  RoundTable Healthcare ... exclusively on the healthcare industry, announced today that ... the newly formed RoundTable III Platform Development Corporation ... Mr. Davies will focus his attention on the ...
... 5, 2012   Synteract , Inc., a full-service contract research ... as senior vice president of sales and marketing and has ... global project management, to support growth in the company and ... COO Stewart Bieler, and CFO Patrik Jeanmonod on the executive ...
Cached Medicine Technology:RoundTable Healthcare Partners Names Kent J. Davies CEO of Newly Formed Platform Development Corporation 2Synteract Expands Executive Roles to Support Growth 2Synteract Expands Executive Roles to Support Growth 3
(Date:3/4/2015)... PA (PRWEB) March 04, 2015 Cook ... non-profit organization that teaches healthy cooking to people touched ... AstraZeneca Hope Lodge. The program, run by founder Ann ... Hospitality and Sport Management. The unique partnership will expand ... Ann Ogden founded CFYL in 2007. After going through ...
(Date:3/4/2015)... More than a year after announcing ... with low testosterone treatments ( http://www.testosteronelawsuithub.com/ ), the U.S. ... now require manufacturers to warn patients that this class ... and strokes. In a Drug Safety Communication ... it was requiring testosterone manufacturers to update the drugs’ ...
(Date:3/4/2015)... Optrix by Body Glove ” was featured on NewsWatch ... a look at the latest and coolest technology products ... reporter for NewsWatch and a technology expert, conducted the ... an ultra-rugged, waterproof case with an interchangeable lens system. ... the Consumer Electronics Show in Las Vegas every year. ...
(Date:3/4/2015)... The popular all-natural supplement brand, Liporidex ... Program. The customized program provides a tailored diet and ... and fitness levels to follow and achieve their weight ... , “We’re really proud to announce our new program ... winning techniques to help people according to their specific ...
(Date:3/4/2015)... Information Innovators Inc . (Triple-i) is honored ... the company as Chief Technology Officer. Mr. Dvorak will ... company, including customer-centric strategies and initiatives, and promoting continuous ... as a technology executive and visionary. Prior to joining ... including oversight of enterprise data management, analytic software development, ...
Breaking Medicine News(10 mins):Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:A Waterproof Phone Case with an Interchangeable Lens System was Featured on NewsWatch Television on January 30, 2015 2Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 3
... 7 (HealthDay News) -- In November, the U.S. Food and ... the treatment of breast cancer. But, a new study ... with a specific type of aggressive breast tumor when used ... (bevacizumab) had been approved in the United States in 2008 ...
... the fierce national debate over a new federal law ... widely assumed that private health insurance can do a ... U.S. government. But a first-of-its-kind analysis of newly ... comes to infants covered by insurance. Among the ...
... HealthDay Reporter , WEDNESDAY, Dec. 7 (HealthDay News) ... with low-risk prostate cancer, a new draft report released ... concluded that research on the safety of "active surveillance" ... men opt for surgery or other treatments that can ...
... have altered natural bioelectrical communication among cells to directly ... at a particular location within a vertebrate organism. Using ... biologists at Tufts University,s School of Arts and Sciences ... of the head area. The researchers achieved most ...
... California,s low-income seniors with disabilities are struggling to remain in ... and may be slashed even further, according to a new ... with support from The SCAN Foundation. Should ... to In-Home Supportive Services (IHSS) on Dec. 15, as proposed ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Dec. 7 ... through strategically placed "seeds" had double the risk of a ... their entire breast, new research finds. This type ... side effects, including infection, according to the study. "We ...
Cached Medicine News:Health News:Avastin Boosted Survival for Type of Aggressive Breast Cancer: Study 2Health News:Public health insurance offers insured infants better, less costly care than private plans 2Health News:Public health insurance offers insured infants better, less costly care than private plans 3Health News:Public health insurance offers insured infants better, less costly care than private plans 4Health News:Public health insurance offers insured infants better, less costly care than private plans 5Health News:Active Surveillance May Benefit Men With Low-Risk Prostate Cancer 2Health News:Researchers discover that changes in bioelectric signals cause tadpoles to grow eyes in back, tail 2Health News:Researchers discover that changes in bioelectric signals cause tadpoles to grow eyes in back, tail 3Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 2Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 3Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 4Health News:Targeted Radiation May Not Be Better for Breast Cancer 2Health News:Targeted Radiation May Not Be Better for Breast Cancer 3
... stents that save inventory, shelf space, and ... lengths from 22 cm to 28 cm. ... to glide over any guidewire and through ... ease of placement and patient comfort in ...
... internal drainage from the ureteropelvic junction to ... for ease of placement and patient compliance. ... for repositioning and ease of removal. AQ® ... that when activated, attracts and holds water ...
The CMV IgM enzyme immunoassay is for the qualitative detection of antibodies to cytomegalovirus. The CMV IgM assay is primarily indicated for the detection of early or recent infection....
The Shandon Sequenza uses the Shandon Coverplate system which ensures consistency and excellent staining quality. , , ,Allows the user to perform large immunostaining runs (up to 50 slides/run...
Medicine Products: